US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Lytix Biopharma to present at the ‘Frontiers in Cancer Immunotherapy 2023’, invited by New York Academy of Sciences

Oslo, 3 May 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company – is pleased to announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, today will give an oral presentation at the ‘Frontiers in Cancer Immunotherapy 2023’ conference, which is taking place in New York, USA.Dr Rekdal has been invited by the New York Academy of Sciences to discuss how tumor-directed strategies enable superior immune-stimulation of ‘cold’ non-infiltrated tumors, in a joint presentation with Lorenzo Galluzzi, PhD, Weill Cornell Medicine. In his

Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February

Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, will release its fourth quarter and second half 2022 results on Thursday, 16 February 2023 at 8am CEST. The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 2:30pm CEST.We encourage you to send us questions in advance, to be addressed during the Q&A session. Please send your email to post@lytixbiopharma.com. The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here:  https://forms.

Lytix Biopharma announces expansion of the ATLAS-IT-05 study to Europe

Oslo, 14 November 2022. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, today announces site activation for the ATLAS-IT-05 study in three European countries.ATLAS-IT-05 is a Phase II combination study evaluating LTX-315 and pembrolizumab in patients with advanced melanoma. The study was initiated at MD Anderson Cancer Center in 2021 and is currently ongoing in the US. The objective of the study is to document whether LTX-315 in combination with pembrolizumab is effective in inducing tumor responses in patients who have failed prior anti PD 1/PD

Lytix Biopharma presents compelling data in collaboration with research groups at National Cancer Institute and Weill Cornell Medicine, USA.

Oslo, 10 November 2022. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian clinical-stage immune-oncology company, today announces the release of new data describing how LTX-315 treatment activates specific immune cells that are critical for a proper priming of tumor-specific T cells.The data will be presented as a poster at the Society for Immunotherapy of Cancer´s 37th Annual Meeting (SITC 2022) in Boston, USA. The poster entitled “Molecular mechanisms of DC activation by melanoma cells responding to LTX-315” describes how dendritic cells (DCs) can be activated by

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe